Literature DB >> 22012955

Oxygen cycling in conjunction with stem cell transplantation induces NOS3 expression leading to attenuation of fibrosis and improved cardiac function.

Mahmood Khan1, Sarath Meduru, Rajan Gogna, Esha Madan, Lucas Citro, Muthulakshmi L Kuppusamy, Muzzammil Sayyid, Mahmoud Mostafa, Robert L Hamlin, Periannan Kuppusamy.   

Abstract

AIMS: Myocardial infarction (MI) is associated with irreversible loss of viable cardiomyocytes. Cell therapy is a potential option to replace the lost cardiomyocytes and restore cardiac function. However, cell therapy is faced with a number of challenges, including survival of the transplanted cells in the infarct region, which is characterized by abundant levels of oxidants and lack of a pro-survival support mechanism. The goal of the present study was to evaluate the effect of supplemental oxygenation on cell engraftment and functional recovery in a rat model. METHODS AND
RESULTS: MI was induced in rats by a 60-min occlusion of the coronary artery, followed by restoration of flow. Mesenchymal stem cells (MSCs), isolated from adult rat bone marrow, were transplanted in the MI region. Rats with transplanted MSCs were exposed to hyperbaric oxygen (HBO: 100% O(2), 2 atmospheres absolute) for 90 min, 5 days/week for 4 weeks. The experimental groups were: MI (control), Ox (MI + HBO), MSC (MI + MSC), and MSC + Ox (MI + MSC + HBO). HBO exposure (oxygenation) was started 3 days after induction of MI. MSCs were transplanted 1 week after induction of MI. Echocardiography showed a significant recovery of cardiac function in the MSC + Ox group, when compared with the MI or MSC group. Oxygenation increased the engraftment of MSCs and vascular density in the infarct region. Molecular analysis of infarct tissue showed a four-fold increase in NOS3 expression in the MSC + Ox group compared with the MI group.
CONCLUSIONS: The results showed that post-MI exposure of rats to daily cycles of hyperoxygenation (oxygen cycling) improved stem cell engraftment, cardiac function, and increased NOS3 expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22012955      PMCID: PMC3243040          DOI: 10.1093/cvr/cvr277

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  46 in total

Review 1.  Nitric oxide: an emerging role in cardioprotection?

Authors:  R D Rakhit; M S Marber
Journal:  Heart       Date:  2001-10       Impact factor: 5.994

2.  Hydrogen peroxide activates endothelial nitric-oxide synthase through coordinated phosphorylation and dephosphorylation via a phosphoinositide 3-kinase-dependent signaling pathway.

Authors:  Shane R Thomas; Kai Chen; John F Keaney
Journal:  J Biol Chem       Date:  2001-12-13       Impact factor: 5.157

3.  Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor.

Authors:  K A Vincent; K G Shyu; Y Luo; M Magner; R A Tio; C Jiang; M A Goldberg; G Y Akita; R J Gregory; J M Isner
Journal:  Circulation       Date:  2000-10-31       Impact factor: 29.690

4.  Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide.

Authors:  G R Drummond; H Cai; M E Davis; S Ramasamy; D G Harrison
Journal:  Circ Res       Date:  2000-02-18       Impact factor: 17.367

Review 5.  Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research.

Authors:  R Bolli
Journal:  J Mol Cell Cardiol       Date:  2001-11       Impact factor: 5.000

6.  Bone marrow cells regenerate infarcted myocardium.

Authors:  D Orlic; J Kajstura; S Chimenti; I Jakoniuk; S M Anderson; B Li; J Pickel; R McKay; B Nadal-Ginard; D M Bodine; A Leri; P Anversa
Journal:  Nature       Date:  2001-04-05       Impact factor: 49.962

7.  Regulation by reactive oxygen species of interleukin-1beta, nitric oxide and prostaglandin E(2) production by human chondrocytes.

Authors:  M Mathy-Hartert; G P Deby-Dupont; J-Y L Reginster; N Ayache; J-P Pujol; Y E Henrotin
Journal:  Osteoarthritis Cartilage       Date:  2002-07       Impact factor: 6.576

8.  Autologous bone-marrow stem-cell transplantation for myocardial regeneration.

Authors:  Christof Stamm; Bernd Westphal; Hans-Dieter Kleine; Michael Petzsch; Christian Kittner; Heiko Klinge; Carl Schümichen; Christoph A Nienaber; Mathias Freund; Gustav Steinhoff
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

9.  Chronic hypoxia increases endothelial nitric oxide synthase generation of nitric oxide by increasing heat shock protein 90 association and serine phosphorylation.

Authors:  Yang Shi; John E Baker; Chenyang Zhang; James S Tweddell; Jidong Su; Kirkwood A Pritchard
Journal:  Circ Res       Date:  2002-08-23       Impact factor: 17.367

10.  Trimetazidine, administered at the onset of reperfusion, ameliorates myocardial dysfunction and injury by activation of p38 mitogen-activated protein kinase and Akt signaling.

Authors:  Mahmood Khan; Sarath Meduru; Mahmoud Mostafa; Saniya Khan; Kàlmàn Hideg; Periannan Kuppusamy
Journal:  J Pharmacol Exp Ther       Date:  2010-02-18       Impact factor: 4.030

View more
  21 in total

1.  Carvedilol enhances mesenchymal stem cell therapy for myocardial infarction via inhibition of caspase-3 expression.

Authors:  Fatemat Hassan; Sarath Meduru; Kazuaki Taguchi; M Lakshmi Kuppusamy; Mahmoud Mostafa; Periannan Kuppusamy; Mahmood Khan
Journal:  J Pharmacol Exp Ther       Date:  2012-06-27       Impact factor: 4.030

2.  Gene expression analysis reveals inhibition of radiation-induced TGFβ-signaling by hyperbaric oxygen therapy in mouse salivary glands.

Authors:  Linda Spiegelberg; Sigrid M A Swagemakers; Wilfred F J Van Ijcken; Edwin Oole; Eppo B Wolvius; Jeroen Essers; Joanna A M Braks
Journal:  Mol Med       Date:  2014-07-10       Impact factor: 6.354

Review 3.  Hyperbaric oxygen, vasculogenic stem cells, and wound healing.

Authors:  Katina M Fosen; Stephen R Thom
Journal:  Antioxid Redox Signal       Date:  2014-05-19       Impact factor: 8.401

4.  MicroRNA-133a engineered mesenchymal stem cells augment cardiac function and cell survival in the infarct heart.

Authors:  Duaa Dakhlallah; Jianying Zhang; Lianbo Yu; Clay B Marsh; Mark G Angelos; Mahmood Khan
Journal:  J Cardiovasc Pharmacol       Date:  2015-03       Impact factor: 3.105

Review 5.  Oxygen Delivery Approaches to Augment Cell Survival After Myocardial Infarction: Progress and Challenges.

Authors:  Alireza Jenabi; Rouhollah Mehdinavaz Aghdam; S A Seyyed Ebrahimi; Seyed Hossein Ahmadi Tafti; Sasirekha Krishnan; K Shoma Suresh; Murugan Ramalingam
Journal:  Cardiovasc Toxicol       Date:  2021-09-20       Impact factor: 3.231

6.  High oxygen preservation hydrogels to augment cell survival under hypoxic condition.

Authors:  Hong Niu; Chao Li; Ya Guan; Yu Dang; Xiaofei Li; Zhaobo Fan; Jie Shen; Liang Ma; Jianjun Guan
Journal:  Acta Biomater       Date:  2020-01-15       Impact factor: 8.947

7.  CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen - changes with oxygen dosage.

Authors:  Marvin Heyboer; Tatyana N Milovanova; Susan Wojcik; William Grant; Mary Chin; Kevin R Hardy; David S Lambert; Christopher Logue; Stephen R Thom
Journal:  Stem Cell Res       Date:  2014-02-28       Impact factor: 2.020

8.  Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis.

Authors:  Daniel A Rossignol
Journal:  Med Gas Res       Date:  2012-03-15

Review 9.  PTEN as a Therapeutic Target in Pulmonary Hypertension Secondary to Left-heart Failure: Effect of HO-3867 and Supplemental Oxygenation.

Authors:  Yazhini Ravi; Chittoor B Sai-Sudhakar; Periannan Kuppusamy
Journal:  Cell Biochem Biophys       Date:  2021-06-16       Impact factor: 2.194

10.  Long course hyperbaric oxygen stimulates neurogenesis and attenuates inflammation after ischemic stroke.

Authors:  Ying-Sheng Lee; Chung-Ching Chio; Ching-Ping Chang; Liang-Chao Wang; Po-Min Chiang; Kuo-Chi Niu; Kuen-Jer Tsai
Journal:  Mediators Inflamm       Date:  2013-02-21       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.